What is the specific price of Tarlatamab-Imdelltra?

Tarlatamab-Imdelltra is a bispecific antibody used to activate the patient's own T cells to attack tumors. Its main purpose is to treat small cell lung cancer (ES-SCLC). This type of drug bridges tumor surface-specific antigens with T cell CD3 receptors, allowing T cells to directionally recognize and kill cancer cells, thus exerting potential anti-tumor effects in patients for whom traditional therapies have limited efficacy. Its treatment model is different from simple chemotherapy or targeted drugs, but combines the natural killing ability of the immune system to achieve more precise tumor control. It is especially suitable for patients with advanced stage, recurrence or resistance to standard treatments.

Currently, talatumumab is not yet on the market in China, nor is it included in medical insurance, so domestic patients cannot obtain the drug through conventional channels. In overseas markets, talatumumab is available in two specifications: American version and European version, 1mg and 10mg respectively. The price range of a single treatment ranges from 20,000 to more than 100,000 yuan. The specific cost will vary depending on the supplier, the country and insurance coverage. It is worth noting that there is currently no generic version of the drug, so the price is relatively fixed, and purchase channels mainly rely on overseas regular hospitals and certified international medical supply chains. Patients need to obtain it through doctor guidance and legal channels.

In clinical practice, before using talatumumab, it is usually necessary to detect the patient's tumor antigen expression, and evaluate the immune system status and previous treatment history to ensure the safety and efficacy of the drug. At the same time, due to its immune activation mechanism, cytokine release and immune-related side effects need to be monitored during treatment, and intervention should be carried out when necessary.

Overall, talatumumab provides a new treatment option for patients with small cell lung cancer and some neuroendocrine tumors. Its innovative immune redirection mechanism represents the cutting-edge direction of cancer immunotherapy. However, patients need to comprehensively evaluate risks, economic conditions and legal access channels when using it to ensure efficacy and safety.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html